Latest Sutro Biopharma Stories
SAN FRANCISCO, Jan. 31, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment of Edward C. Albini as chief financial officer. Mr. Albini has more than 25 years of life science industry experience, including more than 14 years in various financial management positions at Genentech. "Ed...
SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced a collaboration with Sanofi Pasteur -- the largest company entirely dedicated to vaccines -- to produce two undisclosed vaccine candidates. "This collaboration highlights the potential value of Sutro's biochemical synthesis technology for the production of vaccines and...
SAN FRANCISCO, Oct. 24, 2012 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, today announced the expansion of its senior management team with the appointments of Jeremy Bender, Ph.D., as chief business officer and Aaron K. Sato, Ph.D., as vice president, research. "These appointments reflect an important step in the growth of...
SAN FRANCISCO, June 14, 2012 /PRNewswire/ -- Sutro Biopharma today announced that it has signed a licensing agreement with The Scripps Research Institute and will have access to "click chemistry," a modular synthetic approach that allows the assembly of new molecular entities by efficiently and reliably joining two molecular units together stably and irreversibly. The agreement with Scripps Research provides Sutro with a worldwide license to apply click chemistry for the synthesis of...
SAN FRANCISCO, Jan. 7, 2012 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed James A. Wells, Ph.D., and James R. Swartz, Sc.D., to its newly formed scientific advisory board (SAB). Prof. Wells will serve as Chairman of the SAB. "We have brought together two leading scientific experts in the field of protein engineering to provide valuable...
SAN FRANCISCO, Oct. 17, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company's proprietary biochemical protein synthesis technology platform for the synthesis and manufacturing of novel protein therapeutics will be presented at the BioProduction 2011 conference in Berlin. Trevor Hallam, Ph.D., chief scientific officer of Sutro, will present the...
SAN FRANCISCO, May 19, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that a study published in the July issue of Biotechnology and Bioengineering demonstrates that the company's biochemical protein synthesis technology platform enables fast and high-yield protein synthesis and scale-up with straightforward downstream purification processes. In the study, the...
SAN FRANCISCO, Jan. 7, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics. Under the terms of the agreement, Sutro Biopharma will receive an upfront payment of an undisclosed amount, and Pfizer will provide...
SAN FRANCISCO, Dec. 8, 2010 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing both novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed Trevor Hallam, Ph.D., as chief scientific officer (CSO). Dr. Hallam will lead Sutro's ongoing efforts in the application of the company's proprietary protein biochemical synthesis platform for the research and development of novel and biosuperior therapeutics,...
SAN FRANCISCO, Nov. 17, 2010 /PRNewswire/ -- Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and advance the company's biochemical protein synthesis platform to meet current Good Manufacturing Practice (cGMP) standards. Led by Skyline Ventures, the financing round, which consists of two tranches, includes...
